Christopher Dumont
Overview
Christopher Dumont is a counsel in Crowell & Moring’s Brussels office and is a member of the Intellectual Property Group.
Christopher advises and assists clients on a wide range of IP/IT law matters, both contentious and non-contentious, focusing on life sciences litigation. He has extensive experience advising and litigating complex trademark and patent disputes such as SPCs, SPC manufacturing waivers, and the Bolar exemption. He has also developed strong knowledge in advisory and litigation matters before European courts, regarding, among other things, data exclusivity and market protection issues related to pharmaceuticals.
Before joining Crowell as a senior associate in February 2022, Christopher worked for three and a half years at a leading Belgian law firm.
Career & Education
- Catholic University of Leuven, B.A., honours program, 2015
- Catholic University of Leuven, J.D., honours program, 2017
- Catholic University of Leuven, LL.M., intellectual property law, 2018
- Belgium
- European Court
- Dutch
- English
- French
Kristof Roox and Christopher Dumont are able to deliver within tight deadlines. They bring innovative ways to help customers, excellent collaboration within a group of customers. Clear when conveying information and summaries.
— Legal 500, 2024
Christopher's Insights
Client Alert | 5 min read | 03.30.26
The EU Pharma Package: The Transferable Exclusivity Voucher Compromise Proposal
In our third alert in this EU Pharma Package Series, we provided a detailed overview of the diverging positions of the European Commission, the European Parliament , and the Council of the European Union on the transferable exclusivity voucher (TEV) for priority antimicrobials.
Client Alert | 5 min read | 03.22.26
The EU Pharma Package: Regulatory Data Protection Compromise Proposal
Client Alert | 2 min read | 03.12.26
Publication | 02.03.26
Drowning in EU regulations? Five tips for surviving the deluge of new rules
Representative Matters
- Assisting leading pharmaceutical companies in preliminary injunction proceedings regarding generic versions of blockbuster medicinal products.
- Assisting one of the largest tobacco companies in a multilayered cross-border trademark litigation against a spread-out network of infringers.
- Assisting a leading financial company in the development and maintenance of their trademark portfolio.
- Assisting a major Belgian book publisher in complex litigation and investigation by court-appointed expert concerning the publishing and audiovisual rights attached to a graphic character.
- Negotiating a global software license for a consortium of companies in the recycling industry.
- Assisting a European public-private partnership with the supply of data protection and related services.
Christopher's Insights
Client Alert | 5 min read | 03.30.26
The EU Pharma Package: The Transferable Exclusivity Voucher Compromise Proposal
In our third alert in this EU Pharma Package Series, we provided a detailed overview of the diverging positions of the European Commission, the European Parliament , and the Council of the European Union on the transferable exclusivity voucher (TEV) for priority antimicrobials.
Client Alert | 5 min read | 03.22.26
The EU Pharma Package: Regulatory Data Protection Compromise Proposal
Client Alert | 2 min read | 03.12.26
Publication | 02.03.26
Drowning in EU regulations? Five tips for surviving the deluge of new rules
Recognition
IAM Patent 1000: Litigation and Transactions, Recommended, 2025
Christopher's Insights
Client Alert | 5 min read | 03.30.26
The EU Pharma Package: The Transferable Exclusivity Voucher Compromise Proposal
In our third alert in this EU Pharma Package Series, we provided a detailed overview of the diverging positions of the European Commission, the European Parliament , and the Council of the European Union on the transferable exclusivity voucher (TEV) for priority antimicrobials.
Client Alert | 5 min read | 03.22.26
The EU Pharma Package: Regulatory Data Protection Compromise Proposal
Client Alert | 2 min read | 03.12.26
Publication | 02.03.26
Drowning in EU regulations? Five tips for surviving the deluge of new rules
Insights
Drowning in EU regulations? Five tips for surviving the deluge of new rules
|02.03.26
Life Sciences Intellectual Property Review (LSIPR)
Standing to litigate and effects on remedies
|01.01.20
ICIP 2020, Vol. 2, 317-359
"FRAND licensing", Young EPLaw Congress, Brussels
|04.28.25
Practices
- Intellectual Property — Brussels Practice
- Intellectual Property Litigation
- Dispute Resolution — Brussels Practice
- Intellectual Property
- Digital Advertising
- Technology, Media, and Telecommunications — Brussels Practice
- Brussels Practice
- Digital Health and Health Information Technology
- Life Sciences — Intellectual Property
- Life Sciences
- Life Sciences — Brussels Practice
Industries
Christopher's Insights
Client Alert | 5 min read | 03.30.26
The EU Pharma Package: The Transferable Exclusivity Voucher Compromise Proposal
In our third alert in this EU Pharma Package Series, we provided a detailed overview of the diverging positions of the European Commission, the European Parliament , and the Council of the European Union on the transferable exclusivity voucher (TEV) for priority antimicrobials.
Client Alert | 5 min read | 03.22.26
The EU Pharma Package: Regulatory Data Protection Compromise Proposal
Client Alert | 2 min read | 03.12.26
Publication | 02.03.26
Drowning in EU regulations? Five tips for surviving the deluge of new rules
